pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
the cabinet
Drugs
6,918
products tracked
★ save view
↓
export CSV
search
phase
all
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
sort
catalysts
recent
name
therapeutic area
all
Oncology
1831
Infectious Disease
718
Cardiology
425
Pulmonology
396
Immunology
371
Ophthalmology
368
Dermatology
300
Women's Health
131
view
list
cards
Phase 3
vezocolmitide hydrochloride
vezocolmitide hydrochloride
Keratoconjunctivitis Sicca (Dry Eye)
Stuart Therapeutics Inc
Marketed
vibegron
Gemtesa (vibegron)
Overactive Bladder
Sumitomo Pharma America Inc
Phase 3
vicadrostat
vicadrostat
Diastolic Heart Failure (HFpEF)
Boehringer Ingelheim International GmbH
← prev
page 228 of 231
next →
Pain
89
Neurology
1
Phase 2
vididencel
vididencel [INN]
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Mendus AB
Phase 3
vidofludimus calcium
vidofludimus calcium
Relapsing Remitting Multiple Sclerosis (RRMS)
$IMUX
IMMUNIC, INC.
Phase 2
vilastobart
vilastobart
Cervical Cancer
$XLO
Xilio Therapeutics, Inc.
Marketed
vilazodone hydrochloride
Viibryd (vilazodone hydrochloride)
Major Depressive Disorder
Allergan Sales LLC
Phase 2
vilobelimab
Gohibic (vilobelimab)
Acute Respiratory Distress Syndrome
InflaRx NV
Marketed
viloxazine hydrochloride ER
Qelbree (viloxazine hydrochloride)
Attention Deficit Hyperactivity Disorder (ADHD)
$SUPN
SUPERNUS PHARMACEUTICALS, INC.
Marketed
viltolarsen
Viltepso (viltolarsen)
Duchenne Muscular Dystrophy
NS Pharma Inc
Marketed
vimseltinib
Romvimza (vimseltinib)
Graft Versus Host Disease (GVHD)
Ono Pharmaceutical Co Ltd
Marketed
vinblastine sulfate
Vinblastine Sulfate
Letterer-Siwe Disease (Multifocal and Multisystemic (Diss…
Fresenius Kabi USA LLC
Phase 2
vinorelbine tartrate
Vinorelbine Tartrate
Soft Tissue Sarcoma
Taiwan Liposome Co Ltd
Phase 2
visepegenatide
visepegenatide [INN]
Type 2 Diabetes
PegBio Co Ltd
Marketed
vismodegib
Erivedge (vismodegib)
Basal Cell Carcinoma (Basal Cell Epithelioma)
Genentech Inc
Phase 1
vispacabtagene regedleucel
vispacabtagene regedleucel
B-Cell Non-Hodgkin Lymphoma
$CRBU
Caribou Biosciences, Inc.
Phase 2
visugromab
visugromab
Metastatic Hepatocellular Carcinoma (HCC)
Catalym GmbH
Preclinical
vitamin A palmitate
Bronchopulmonary Dysplasia
Advent Therapeutics Inc
Phase 1
vobramitamab tavatecan
vobramitamab tavatecan[INN]
Bladder Cancer
$MGNX
MACROGENICS INC
Phase 2
vocacapsaicin hydrochloride
vocacapsaicin hydrochloride
Post-Operative Pain
Concentric Analgesics Inc
Phase 2
vodobatinib
vodobatinib
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Sun Pharma Advanced Research Company Ltd
Phase 2
volagidemab
volagidemab
Type 1 Diabetes (Juvenile Diabetes)
Remd Biotherapeutics Inc
Phase 2
volixibat potassium
volixibat potassium
Pruritus
$MIRM
Mirum Pharmaceuticals, Inc.
Marketed
von willebrand factor (recombinant)
Vonvendi (von willebrand factor (recombinant))
Von Willebrand Disease (vWD)
Baxalta Inc
Phase 2
vonafexor
vonafexor [INN]
Alport Syndrome
Enyo Pharma SA
Phase 3
vonaprument
vonaprument
Geographic Atrophy
$ANNX
Annexon, Inc.
Phase 2
vopimetostat
vopimetostat [INN]
Bladder Cancer
$TNGX
Tango Therapeutics, Inc.
Marketed
vorasidenib citrate
Voranigo (vorasidenib citrate)
Low-Grade Glioma
Les Laboratoires Servier SAS
Phase 2
voretigene neparvovec
Luxturna (voretigene neparvovec-rzyl)
Choroideremia
F. Hoffmann-La Roche Ltd
Marketed
vorinostat
Zolinza (vorinostat)
Cutaneous T-Cell Lymphoma
$MRK
Merck & Co., Inc.
